期刊文献+

阿托伐他汀联合稳心颗粒治疗阵发性房颤疗效观察 被引量:4

Clinical observation of Atorvastatin combined with Wenxin Granules in the treatment of paroxysmal atrial fibrillation
下载PDF
导出
摘要 目的:探讨阿托伐他汀联合稳心颗粒治疗阵发性房颤的临床疗效。方法:随机选取阵发性房颤患者94例,分为治疗组(阿托伐他汀稳心颗粒组)和对照组(胺碘酮组)。治疗组口服阿托伐他汀联合稳心颗粒,对照组口服胺碘酮,随访12个月,观察两组的疗效。结果:治疗组窦性心律维持率高,房颤复发率明显下降(P<0.05),心功能明显改善(P<0.05),左室射血分数(LVEF)明显提高(P<0.05),左房内经(LAD)明显缩小(P<0.05),C反应蛋白(CRP)水平显著降低(P<0.01),与对照组比较,差异均有统计学意义。结论:阿托伐他汀联合稳心颗粒能更有效预防阵发性房颤复发。 Objective:To observe the effect of Atorvastatin combined with Wenxin Granules in the treatment of paroxysmal atrial fibrillation.Methods:94 paroxysmal atrial fibrillation patients were enrolled and randomly divided into treatment group and control group.The treatment group were treated with Atorvastatin and Wenxin Granules,and the control group only with Amiodarone.Followed up 12 months,we observed the effect of two groups.Results:Compared with the control group,the sinus rhythm maintenace rate in treatment group was higher,and the recurrence rate in treatment group was lower,heart function improved obviously,LVEF increased remarkably,LAD shrank obviously,CRP levels were lower,there were significant differences statistically in comparison between two groups.Conclusion:Atorvastatin combined with Wenxinkeli can be used to treat patients with paroxysmal atrial fibrillation and prevent the recurrence.
作者 万素芹 徐珞
出处 《中国医药导报》 CAS 2010年第22期101-102,共2页 China Medical Herald
关键词 阵发性房颤 阿托伐他汀 稳心颗粒 胺碘酮 Paroxysmal atrial fibrillation Atorvastatin Wenxinkeli Amiodarone
  • 相关文献

参考文献6

二级参考文献55

  • 1邢燕,陈红,胡大一.停用他汀类药物对血管内皮一氧化氮合成的影响[J].中华内科杂志,2005,40(1):22-24. 被引量:7
  • 2胡大一,孙艺红.血栓栓塞性疾病的规范防治——ACCP最新溶栓和抗栓指南的启示[J].临床荟萃,2005,20(15):841-843. 被引量:16
  • 3叶行舟,智宏,黄玉,许桦,王惠萍,王润民.射频消融术心肌损伤的评价[J].临床荟萃,2005,20(23):1347-1348. 被引量:1
  • 4章慧洁.心律失常[J].中国医学文摘(内科学),2005,26(6):692-694. 被引量:1
  • 5Lee JD, Morrissey JR, Mikhailidis DP,et al. CARDS on the table:shouid everybody with type 2 diabetes take a statin[J]? Curr Med Res Opin, 2005,3 : 357-362.
  • 6Guclu F, Ozmen B, Hekimsoy Z,et al. Effects of a statin group drug, pravastatin;on the insulin resistance in patients with metabolic syndrong[J]. Bioned Pharmacother, 2004,10: 614-618.
  • 7Solomon DH, Finkelstein JS, Wang PS, et al. Statin lipidlowering drugs and bone mineral density[J]. Pharmaeoepidemiol Drug Saf, 2005,14:219-226.
  • 8Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bonemineral density, and fracture risk: Geelong Osteoporosis Study [J]. Arch Intern Med,2002,162:537-540.
  • 9Lupattelli G, Scarponi AM. Vatudo C, et al. Simvastatin increases bone mineral density in hypercholsterolemic postmenopausal women[J]. Metabolism, 2004,53 : 744-748.
  • 10Hatzigeorgiou C, Jackson JL Hydroxymethylalutary a reductase inhibitour and osteoporosis: a metaanalysis(J). Osteoporos Int, 2005,16(8) : 990-998.

共引文献107

同被引文献89

引证文献4

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部